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ABSTRACT 
We created and tested multi-epitope DNA or protein vaccines with TLR4 ligand 
emulsion adjuvant (gluco glucopyranosyl lipid adjuvant in a stable emulsion (GLA-SE)) 
for their ability to protect against Toxoplasma gondii in HLA transgenic mice. Our 
constructs each included five of our best down selected CD8
+
T cell eliciting epitopes, an 
universal CD4
+
 helper T lymphocyte epitope (PADRE), a secretory signal, all arranged 
for optimal MHC Class I presentation. Their capacity to elicit immune and protective 
responses was studied using immunization of HLA-A*1101 transgenic mice. These 
multi-epitope vaccines increased memory CD8
+ 
T cells that produced IFN-γ and 
protected mice against parasite burden when challenged with T. gondii. Endocytosis of 
emulsion-trapped protein and cross presentation of the antigens must account for the 
immunogenicity of our adjuvanted protein. Thus, our work creates a novel adjuvanted 
platform assembly of peptides resulting in cross presentation of CD8
+ 
T cell eliciting 
epitopes in a vaccine that prevents toxoplasmosis. 
Keywords: Toxoplasma gondii, HLA-A*1101, vaccine, DNA, multi-epitope protein. 
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INTRODUCTION 
Toxoplasma gondii is an intracellular parasite that can cause severe ocular and 
neurological diseases in the fetus, newborn infants and immunocompromised individuals 
(1). The acute infection is characterized by proliferation of tachyzoites, which replicate 
rapidly within host cells and lyse their host cells within 24Ð48 hours to release large 
numbers of progeny. In response to immune pressure, the parasite differentiates into a 
slow growing form called bradyzoites, which resides within intracellular cysts. Formation 
of tissue cysts normally occurs in long-lived cells such as muscle or neuronal cells. 
 
Although anti-parasitic medicines such as sulfadiazine and pyrimethamine are effective 
against tachyzoites, they are associated with toxicity or hypersensitivity and do not 
eliminate the latent, the cyst form of the parasite (2). Thus, there is a need for 
development of a safe, protective vaccine. Our recent work has focused on development 
of an epitope-based vaccine for toxoplamosis to enhance host immunity by stimulating 
efficacious responses of CD4
+
 helper T lymphocytes (HTLs) and CD8
+
 IFN-γ-producing 
T lymphocytes (3-6) for humans. These CD8
+
 T cells recognize the octamer/nonamer 
peptides presented by HLA supermotif major histocompatibility complex class I (MHC-I) 
molecules on antigen presenting cells (APCs) in humans (3-6). Considerable effort has 
been made to identify promising vaccine candidate antigens for T. gondii. Using 
bioinformatic analyses, multiple predicted CD8
+
 epitopes of tachyzoite- and bradyzoite-
specific antigens have recently entered our vaccine development pipeline (3-6). 
Candidate amino acid sequences are from surface antigens (SAG1 and SUSA1) and 
secreted proteins, including dense granule proteins (GRA2, GRA3, GRA6, GRA7) and 
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rhoptry proteins (ROP2, ROP16, ROP18). We reported in our previous studies CD8
+
 
epitopes derived from these antigens that can be presented by HLA-A02, HLA-A03 and 
HLA-B07 human major histocompatibility complex (MHC) molecules (3-6). These CD8
+
 
T cell-restricted peptides administered with a universal helper T cell epitope, PADRE and 
adjuvants elicit IFN-γ and reduce parasite burden in HLA-B*0702, HLA-A*1101 and 
HLA- A*0201 transgenic mice. 
 
In the present study, we selected five peptide epitopes, KSFKDILPK (SAG1224-232), 
STFWPCLLR (SAG2C13-21), AVVSLLRLLK (GRA589-98), SSAYVFSVK (SRS52A250-
258), and AMLTAFFLR (GRA6164-172) that elicited IFN-g from peripheral blood 
mononuclear leukocytes (PBMCs) from T. gondii seropositive HLA-A03 supertype 
humans. SAG1 is a surface protein expressed in tachyzoites, and mediates adhesion of 
the parasite to the host cell prior to invasion (7, 8). It is highly conserved in T. gondii 
strains, and shown to induce cellular immune responses in mice (9). SAG2C appears to 
be expressed exclusively on the surface of bradyzoites. SRS52A is one of the surface 
antigen-1-related sequences (SRSs), which comprise a gene family with similar structure 
to the major tachyzoite immunodominant surface antigen, SAG1. GRA6 is expressed and 
secreted by both the tachyzoite and the bradyzoite stages of the parasite. GRA5 another 
dense granule protein is present in bradyzoites and is strongly concentrated in the cyst 
wall (10). 
 
As identification of protective epitopes increases, novel ways to present these 
immunogenic peptide epitopes to a host's immune system are needed. Development of 
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multi-epitope DNA vaccines has been utilized to protect against other pathogens. 
However, immunogenicity of epitope-based DNA vaccines is not yet optimal, as immune 
responses induced by epitope DNA vaccines are often weak (11). In our previous studies 
we produced a prototypic Toxoplasma vaccine based on a highly versatile self-
assembling protein nanoparticle platform that can repetitively display PADRE-GRA720Ð28 
antigenic epitopes and found a 72% reduction of cysts in type II T. gondii infected HLA-
B*0702 transgenic mice (12). Thus, our current study is intended to develop new tools to 
add to a rational design that might be adapted to other platform approaches with CD8
+
 
epitopes that bind to human major histocompatibility complex (HLA) class I molecules 
or be sufficient by themselves to elicit robust protection in humans. 
 
Herein, we selected five potentially protective octamer CD8
+
 T cells eliciting epitopes 
that interact with HLA-A*1101. We generated two polypeptides containing the five 
HLA-A*1101 peptides and PADRE linked with 2 different linkers. We found better 
protection with the K/NAAA linker. This polypeptide administered with TLR4 ligand 
containing emulsion, GLA-SE was more effective than ALUM adjuvant. Furthermore, 
we examined the immunogenicity of a synthetic DNA vaccine encoding the five octamer 
CD8
+
 T cells eliciting epitopes of T. gondii. DNA was delivered by electroporation as 
previously described (13, 14) into HLA-A*1101 transgenic mice and the immunization 
was followed two weeks later by two protein boosts with the multi-epitope recombinant 
protein adjuvanted with a universal CD4
+
 helper T lymphocyte epitope, PADRE, and 
GLA-SE. Immunization of these mice activated CD8
+
 T cells to produce IFN-γ, increase 
memory CD8
+
 T cells and protected against subsequent challenge with a high inoculum 
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of type II parasites. Our results highlight the potential for the use of GLA-SE adjuvanted 
CD8
+
 T cell-restricted epitopes in multi-epitope assemblies as a platform for vaccine 
approach to protect against toxoplasmosis. 
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RESULTS 
Identification of new candidate T. gondii specific HLA-A*1101-restricted epitopes 
We have searched candidate epitopes from T. gondii that show high affinity binding to 
HLA-A*1101 molecules (Table 1). Five peptide epitopes derived from SAG1, SRS52A, 
SAG2C, GRA6 and GRA5 have representative affinities for HLA-A*1101 molecules, a 
haplotype that covered 16-30% population in China; 7-16% in Europe and North 
America; 1.5-10% in South America (www.allelefrequencies.net) (Table 1). 
 
To determine which of these peptides would be recognized in the context of Toxoplasma 
infection, peripheral blood mononuclear cells (PBMC) from T. gondii-seropositive HLA-
A03 individuals were tested for response to these peptides in pools or individually by 
using an IFN-γ ELISpot assay. Candidate peptides were considered immunogenic if they 
induced IFN-γ-secreting spot formation that was significant compared to an irrelevant 
HLA-A*1101-restricted peptide. As shown in Figure 1, there were five peptide pools 
which stimulated significant response by PBMC derived from Toxoplasma seropositive 
HLA-A03 individuals. These were: one from SAG1224-232 (KSFKDILPK), SAG2C13-21 
(STFWPCLLR), GRA589-98 (AVVSLLRLLK), SRS52A250-258 (SSAYVFSVK), and 
GRA6164-172 (AMLTAFFLR). 
 
Specificity of epitopes for HLA A*1101. 
The peptides we selected are HLA-A*1101 specific. This specificity is shown in our 
binding assay where our peptides do not significantly bind to HLA-A*0201 or B*0702 
molecule (Table 1). HLA-A*0201 and B*0702 are among the other most prevalent 
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supermotifs, and our results are consonant with in silico predictions for these haplotypes. 
In table 1, none of the peptides would be considered an A*02.01 or B*07.02 binders. In 
Table 2, relative to the background genes in the C57BL/6J mice, there is specificity of 
presentation of peptides to those that are restricted by HLA-A*1101 by macrophages 
from the transgenic HLA-A*1101 mice, but not presented by macrophages from their 
wild type mouse controls. In earlier work by Tan, McLeod et al; .Cong, McLeod et al. (3, 
5) for all 5 peptides utilized herein, PBMC from 3 T. gondii seropositive HLA-A 03-11 
persons with serum antibody to T. gondii (seropositive) and 3 persons without serum 
antibody to T. gondii (seronegative) were tested. PBMC from all the seropositive persons 
responded to the peptides and no seronegative persons had PBMC that responded with 
IFN-γ production demonstrated by ELISPOT. For peptides and TLA differences were 
highly significant for seropositive and seronegative persons (p < 0.001) whereas 
differences for Concanavalin A were not significant. The response to the peptides is 
specific to the parasite in seropositive persons and not present in those who are 
seronegative. Herein, the peptides were re-tested at the same time for the same HLA A3-
11 seropositive human donor used for our subsequent studies herein. HLA A2, B7 
haplotype seropositive persons (and seronegative persons) whose cells were without 
response to individual peptides or the polyepitope in the ELISPOT for IFNγ in two 
replicate experiments (data not shown). 
 
 
HLA-A*1101-transgenic mice as a model to assess cellular immunogenicity of 5 
identified HLA-A*1101-restricted CD8+ T cell epitope peptides 
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To address the HLA-A11-specific genetic restriction of the 5 HLA-A*1101 epitopes 
(plus a GRA7 peptide) identified to prime for IFN-γ responses, HLA-A*1101-
transgenic mice were immunized subcutaneously. Immunization was with these peptides 
mixed with PADRE, and adjuvants or the adjuvants alone As shown in Table 2, 
robust IFN-g responses from CD8+ T cells from  spleens of mice immunized with 
peptides plus adjuvants were observed following stimulation by the pool of peptides in 
the presence of APC from the HLA-A*1101 transgenic mice but not of APC from wild-
type C57BL/6 mice (Table 2).   Immunization of HLA-A*1101-transgenic mice with 
adjuvants alone did not elicit IFN-g when the CD8
+
 T cells were stimulated either with or 
without peptides (i.e. background levels) (Table 2). 
 
Vaccination with peptide pools, PADRE and GLA-SE adjuvant protects mice and 
increase memory against type II parasite challenge 
HLA-A*1101-transgenic mice were immunized with peptide pools combined with GLA-
SE adjuvant and PADRE three times at intervals of two weeks. PBS was used as control. 
Five weeks after the last immunization, mice were challenged with type II parasites. 
Differences in brain cyst numbers between control and immunized mice were significant 
(p< 0.013) as shown in Figure 2A-B, with the immunized mice having a reduced cyst 
burden. Spleens from unchallenged immunized and control mice were tested for the 
ability of the immunization to induce CD8
+
 T cell memory response. As shown in Figure 
2C-D, there is an increase of memory CD8
+
 T cells in the immunized group. 
 
 10 
LO and AZ multi-epitope polypeptide immunogenicity in vitro 
The CD8
+
 T cell-epitopes identified are intended to form the basis of Toxoplasma 
vaccine for persons with the HLA-A*1101 supertype. We expressed and purified from E. 
coli a protein composed of the five epitopes linked in a sequence with the universal CD4
+
 
T cell epitope, PADRE (AKFVAAWTLKAAA) and the murine Igk-chain signal 
sequence for targeting protein to secretory pathway at the N-terminus. The epitopes were 
linked together with N/K alanines or GPGPG as linker, named as LO and AZ, 
respectively (Figure 3A-B). Both proteins were purified via Ni-NTA affinity column and 
the molecular weight was verified by SDS-PAGE analysis (Figure 3C). Immunogenicity 
of the two proteins compared to the pool of the 5 individual A11-restricted CD8
+
 T cell 
epitope peptides were tested in vitro. Briefly, PBMCs from T. gondii seropositive HLA-
A03 supertype humans were tested for their ability to generate IFN-g in response to the 
stimulation with either LO or AZ protein or a pool of the peptides for 2 days to allow 
time for processing the proteins and presentation thereof to MHC class I. The data in 
Figure 4A-C demonstrate IFN-g secretion was significantly enhanced by stimulation with 
either LO or AZ multi-epitope polypeptide compared with a pool of the individual 5 
epitope peptides (p<0.001). 
 
Herein, the peptides and polyepitope were re-tested at the same time for the same HLA 
A3-11 seropositive human donor used for our subsequent studies herein and HLA A2, B7 
haplotype seropositive persons (and seronegative persons) whose cells were without 
response (data not shown). 
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Immunization with LO and AZ multi-epitope polypeptides with GLA-SE adjuvant confers 
a potent protection in HLA-A*1101 transgenic mice against T. gondii. 
HLA-A*1101 transgenic mice were immunized with a combination of LO and AZ multi-
epitope polypeptides with GLA-SE or ALUM adjuvant. As a control, mice were 
immunized with adjuvant alone or PBS. Mice were then challenged 2 weeks after the last 
immunization with type II strains of T. gondii. As shown in Figure 5, 80% of mice 
immunized with LO and AZ multi-epitope polypeptides emulsified in GLA-SE adjuvant 
survived parasite challenge. In contrast, only 30% of mice immunized with the ALUM 
adjuvant plus polypeptides survived parasite challenge (p<0.05). As a control, neither 
mice immunized with the adjuvant alone nor those immunized with PBS increase their 
survival after challenge (Figure 5). 
 
Prime/ boost strategy: LO and AZ DNA plus multi-epitope polypeptide immunogenicity in 
vivo 
We next addressed whether a prime/boost strategy using DNA encoding the five 
individual epitopes plus PADRE and the polypeptides would confer better protection 
against parasite challenge in HLA-A*1101 mice. We constructed synthetic DNAs in 
which the 5 poly-epitope nucleotides with the N/K alanines or GPGPG linkers plus 
PADRE were cloned in EcoRI and BglII sites of the vaccine vector pMB75.6 (Figure 
6A). During DNA vaccinations, mice were immunized intramuscularly (i.m.) two times 
at 2 weeks interval with 100 µg of LO or AZ DNA vectors followed by another two 
injections of 50 µg of the polypeptides at 2 weeks interval. They were challenged with 
2,000 ME49 (Fluc) 2 weeks after the last immunization. Brains from these mice were 
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imaged 21 days after the challenge using a Xenogen in vivo imaging system to assess 
parasite burden in the brain. As shown in Figure 6B-C, as an additional measure of 
efficacy for protection against challenge with luciferase-expressing parasites, the 
numbers of these parasites in HLA-A*1101 mice immunized with LO or AZ DNA plus 
multi-epitope polypeptide or polypeptides alone were significantly reduced compared to 
the mice immunized with control empty vector or PBS. This correlates with the reduction 
of the number of cysts per brain (Figure 6D). We then analyzed the effect of LO or AZ 
DNA plus multi-epitope polypeptide on IFN-γ expression in vitro. Briefly, mice were 
immunized two times at 2 weeks interval with LO or AZ DNA followed by another two 
injections of either LO polypeptide, AZ polypeptide or ovalbumin peptide as control. 
Negative controls mice were vaccinated twice with empty vector followed by saline. Two 
weeks after the last immunization, mice were sacrificed and splenocytes were harvested 
for immune responses analysis. As shown in Figure 7A, considerable amount of IFN-γ 
expressing CD8
+
 cells were observed following immunization with AZ DNA or LO DNA 
compared with mice immunized with the empty vector. An even more robust response 
was achieved when mice immunized with the vectors expressing the polypeptides were 
stimulated in vitro by the corresponding AZ or LO protein, although the difference was 
only significant in the LO treated mice. In contrast, there was no increase in the amount 
of CD8
+
 IFN-γ producing cells observed when the mice were immunized with AZ or LO 
DNA followed by a challenge with a non-relevant protein, ovalbumin. There was a very 
modest increase in protection when DNA administration precedes administration of 
protein with the LO construct as in survival curves and dot plots (Figure 7B). 
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LO DNA plus multi-epitope LO polypeptide are protective against Toxoplasma challenge 
in HLA-A*1101 transgenic mice 
As shown in Figure 7B, a majority, 7 of 8 (87%) HLA-A*1101 mice immunized with LO 
DNA plus LO polypeptide emulsified in GLA-SE adjuvant survived parasite challenge. In 
contrast, only 1 of 8 (12%) unimmunized mice or immunized with empty vector survived 
parasite challenge. 
 
LO DNA plus multi-epitope polypeptide increases memory CD8
+
 T cell response 
We then analyzed the effect of LO DNA plus multi-epitope polypeptide on the T. gondiiÐ
specific CD8
+
 T cell memory response. This was performed by quantifying the levels of 
memory T cells in the spleen from HLA-A*1101 mice at 35 days after the last 
immunization. As shown in Figure 7C-D, CD8
+
 memory T cells were significantly 
increased in mice immunized with either LO protein alone or LODNA plus LO protein 
compared with mice immunized with the empty vector or PBS. 
 
GLA-SE is a TLR4 ligand that elicits cytokines. 
Demonstration that GLA-SE is a TLR4 ligand is shown schematically and with data in 
Figure 8A eliciting IL6, IL2, and TNFα. We determine whether GLA-SE induces 
cytokine production. As shown in Figure 8A, human whole blood was stimulated with 
GLA-SE for 24 hours. There was an increase of cytokine production in plasma from 
these cultures. Difference between stimulated and unstimulated cultures are significant 
(p<0.05) (Figure 8B). 
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DISCUSSION 
There is a need for improved vaccination and delivery approaches to induce cellular 
immune responses against T. gondii. Earlier, bioinformatics, immunosense approaches 
and empiric studies with human peripheral blood mononuclear cells facilitated 
identification of protective peptide epitopes for HLA-A*1101 supertypes. The most 
immunogenic of these epitopes (KSFKDILPK (SAG1224-232), STFWPCLLR (SAG2C13-
21), AVVSLLRLLK (GRA589-98), SSAYVFSVK (SRS52A250-258), and AMLTAFFLR 
(GRA6164-172)) were then utilized in comparative studies with differing adjuvants and 
delivery methods in the HLA-A*1101 supermotif transgenic mice to characterize 
immune responses and study protection. Herein, we present a novel way to present 
immunogenic peptide epitopes to a hostÕs immune system based on the assembly of five 
protective CD8
+
 T cell epitope for HLA-A*1101-restricted supertypes. These epitopes 
were constructed with the universal CD4
+
 T cell epitope, PADRE linked with N/KAAA 
or GPGPG spacers and a secretory signal. These vaccine design features were 
incorporated to optimize proteasome processing and, subsequently, epitope and vaccine 
immunogenicity. 
 
Improved delivery approaches are important for successful vaccine. This was showed by 
previous studies with another transgenic mouse supertype, HLA-B*07, where T gondiiÐ
specific HLA-B07Ðrestricted CD8
+
 T cell epitope LPQFATAAT derived from GRA720Ð28 
elicited CD8
+
 T cell specific IFN-γ with the help of a universal CD4
+
 epitope and 
adjuvant GLA-SE confered protection of HLA-B07 mice from type II parasite challenge 
(4). The same epitope used in a novel nanoparticle platform was found to have better 
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immunogenicity (12), with 72% reduction of cyst burden in the brains of GRA720Ð28 
nanoparticles-immunized mice compared to 54% reduction with immunization with 
GRA720Ð28 peptide in combination with PADRE and the adjuvant GLA-SE. This work 
provided a foundation for the present study, which is intended to improve vaccination and 
delivery approaches against T. gondii to protect humans. 
 
Herein, we examined the immunogenicity of a multi-epitope protein and synthetic 
consensus DNA, clinically approved mammalian expression vector encoding five T. 
gondii specific HLA-A*1101-restricted epitopes. The DNA plasmid vaccine is encoding 
the five CD8
+
 T cell epitopes restricted by HLA-A*1101 supertype alleles and the 
universal HTL epitope, PADRE. These DNA constructs were optimized using codon 
optimization, leader sequence addition, plasmid production at high concentration and the 
DNA was delivered by electroporation as described (13). Immunization of HLA-A*1101 
mice with recombinant multi-epitope formulated with a Toll-like receptor 4 ligand 
(TLR4)-containing adjuvant (gluco glucopyranosyl lipid adjuvant in a stable emulsion 
[GLA-SE]) induced antigen-specific IFN-γ-producing CD8
+
 T cells in their spleens, 
increase memory CD8
+
 T cells population, and conferred a potent protection against T. 
gondii challenge. The adjuvant ALUM formulated to the recombinant multi-epitope was 
less effective in conferring protection as when compared to the vaccine preparations 
containing GLA-SE. The present study also demonstrated that DNA prime followed by a 
multi-epitope protein-GLA-SE boost is more protective than either of the DNA prime 
followed by ovalbumin (unrelated protein) boost or the recombinant multi-epitope alone. 
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The major limitation of DNA vaccination in the past has been its relatively weak 
immunogenicity in vivo for humans. Electroporation has successfully aided in enhancing 
the delivery of DNA vaccines, leading to the generation of stronger immune responses 
(10Ð100-fold) compared with naked DNA vaccine delivery alone to muscle or skin (15). 
Interestingly, a multi-epitope DNA prime-protein boost also appeared to drive a more 
functionally divergent T-cell response (16). Previous studies have shown that protein and 
DNA only vaccination produced similar numbers of IFN-γ
+ 
cells
 
in both CD4
+
 and CD8
+
 
T-cells, as well as similar numbers of IL-2
+ 
cells in both CD4
+
 and CD8
+
 T-cells (16). In 
contrast, a multi-epitope DNA prime-protein boost resulted in four times more IFN-γ
+
-
secreting CD8
+
 T-cells than IFN-γ
+
-secreting CD4
+
 T-cells and higher IL-2
+
 -secreting 
CD4
+
 and CD8
+
 T-cells (16). Notably, our present study showed that protein prime and 
boost with GLA-SE was also quite effective. The ex vivo stimulation of spleen cells from 
HLA-A*1101 mice and PBMC from HLA-A03 seropositive individuals showed CD8
+
 T 
cells were more responsive to the composite polypeptide than to the pooled or single 
constituent peptides. Processing and presentation of AZ and LO poly-epitope polypeptide 
in human cells occur with high efficiency in LO poly-epitope-stimulated cells. These 
cells demonstrate stronger responses with N/K alanines linker compared to GPGPG. 
 
The polyepitope protein induces a more robust response, compared to single peptides 
with GLA-SE, or lipopeptides with single or three of the peptides, linked, but in a 
different order. In these linked and single peptide lipopeptides, responses are much less 
or absent (3, 5). Other arrangements of sequence in DNA vaccines encoding peptides in 
DNA vaccine or peptides in a non-ionic surfactant vesicles (NISV) also elicited less 
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robust response or were or absent (data not shown). In future studies, when constructs for 
all haplotypes are fully defined and optimized, it will be important to utilize models we 
have developed for ocular, congenital, peroral encysted bradyzoite and oocyst infections, 
as well as immune compromised models of infections (17-24), along with intranasal 
immunizations (Gigly, Dubey, Zhou, McLeod et al., In preparation). 
 
There are a number of aspects of our current approach that make our work herein unique 
and valuable: This work makes a step change forward towards building immunosense 
vaccines for humans. These paradigm changes include: The GLA-SE emulsion leads to 
delivery of peptides from an artificial, polypeptide-epitope protein to both Class I and 
Class II MHC pathways. This is demonstrated by epitope content and effector functions 
they elicit. The polyepitope with a secretory sequence and with peptides arranged so 
cleavage is optimized in such a way that it includes the intended peptides in the protein is 
another step change. This arrangement allows for optimal processing and presentation. 
Computer-based modeling was used to design our vaccine component in this manner (25, 
26). It was designed to optimize proteasome-mediated epitope processing and to 
minimize the creation of junctional epitopes. Junctional epitopes occur by the 
juxtaposition of two epitopes. Altering epitope order and introducing selected amino acid 
spacers at the C terminus of individual epitopes were used to control these properties (25, 
26). This is, to our knowledge, the first and only creation of a artificial protein based on 
immunosense in conjunction with GLA-SE that successfully immunizes HLA transgenic, 
or any, mice, against Toxoplasma gondii. Our use of mouse strains with differing HLA 
supermotif transgenes also makes our work pertinent to begin to protect people globally 
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against Toxoplasma infection with vaccines rather than simply protecting mice against 
this infection. It presents a new paradigm for an immunosense approach for protection 
against human T. gondii and other infections and diseases. Further, we found earlier that 
protection and IFN-γ production following immunization with individual peptides pooled 
or organized with alanine linkers, and linked in lipopeptides, are substantially less robust 
in eliciting IFN-γ and protection (3, 5) than the approach herein with DNA and protein, 
or protein and protein immunizations, in HLA-A*011 transgenic mice. Our earlier 
attempt to include these and many other epitopes that would bind to other supermotifs in 
a Òchain of pearlsÓ DNA vaccine (El Bissati, Dubey, Mui, Roberts, Gigly, McLeod, et al., 
unpublished) administered with electroporation or a peptide in NISV (Roberts, Woods, 
Mui, El Bissati, Dubey, Gigly, McLeod, unpublished data) were unsuccessful other than 
a very small response with the DNA vaccine to the N terminal encoded peptide, 
conferring very modest protection. This was despite finding the peptides by mass 
spectroscopy when the full length construct was delivered as a vector transfected into a 
monocytic cell line (El Bissati, McLeod, unpublished data). 
 
We tried deconvoluting our peptides in a separate study to characterize whether adding a 
homologous mouse CD4
+
 T cell stimulating peptide would enhance protection. We 
present some of these data in another manuscript (El Bissati, McLeod et al, in preparation 
2016). In this work we learned something quite unexpected. Surprisingly, in this other 
study we found that in female mice, this CD4
+
 T cell eliciting nonamer peptide epitope 
which added protection in the combination of peptides, when tested as a single peptide 
administered with GLA-SE, as we deconvoluted peptides, was lethal in the booster, 
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second immunization (El Bissati, Zhou, McLeod et al., manuscript in preparation). This 
lethality was associated with intestinal, hepatic, spleen, and lymph node pathology due to 
the CD4
+
 T cell elicited (El Bissati, Zhou, McLeod et al., manuscript in preparation). 
Without the CD8
+
 T cell eliciting peptides or PADRE, there was a cytokine storm with 
IL6 especially prominent. In contrast to administration of this one peptide with GLA-SE, 
with inclusion of our CD8
+
 peptides or addition of only PADRE there was enhanced 
protection. What we learned is that it is not only the presence of the particular peptide but 
the company it keeps that leads to harmful or enhanced protective immune response. 
Some other recent similar studies make this point a different way. For example, based on 
the recent work of Blanchard et al. (27) it is also location in the entire construct that 
determines immunogenicity and robustness of protection. Similarly, background genes of 
the host, and also the microbiome (from the work of others), influences robustness and 
skewing of immune responses (28-30). We had thought to confirm safety we should 
deconvolute the constituents of our vaccines. What we learned was that immunogenicity 
and protection will depend on the hostÕs genetics and epigenetics, and company the 
peptides keep in the final vaccine for humans. Function of the assembled vaccine 
constituents in the human, not just murine host, will be critical. Our recent work, and 
very recent work of others (27), indicates that efficacy and toxicity are likely to be more 
complex, and ultimately require safety and efficacy testing in humans. 
 
The in vitro and in vivo murine work in the present study indicates that the GLA-SE 
nano-emulsion must provide protein for cross presentation by antigen presenting cells as 
shown schematically in Figure 8. As shown in our experiments herein (Figure 8B) GLA-
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SE is a TLR4 ligand and in multiple other experimental systems and moving into the 
clinic, triggering MYD88 and downstream signaling pathways (31, 32). The GLA-SE 
emulsion entraps proteins in nanoparticle structures of approximately 100 nm with 
multiple associated GLA molecules on their surfaces, although the percentage entrapment 
and precise location of the GLA-SE was not studied herein. Such particles as well as 
proteins that are endocytosed enter a MHC Class II pathway stimulating CD4
+
 T cells 
(33). Herein, we demonstrate both MHC Class I and Class II responses to peptides in our 
constructed protein. It is likely the small particle size (100 nm) is responsible for this 
unusual trajectory to MHC Class I presenting bound peptides to CD8
+
 T cells. The 
effector mechanism restricted by MHC Class I for a peptide defines the cross 
presentation of these antigens. From a polyepitope, that must enter its host cell by 
endocytosis, protein or peptides must leave the endocytic vacuole, and therefore be Òcross 
presentedÓ. Further, since completion of the present work, we also placed this 
polyepitope protein construct with CD8
+
 T cell eliciting epitopes in a Self-Assembling 
Protein Nanoparticle (SAPN) (El Bissati, Zhou, Burkhard, McLeod, in submission). 
Recent electron microscopy studies also demonstrated a malaria SAPN eliciting CD8
+ 
T 
cells with localization to the proteasome and delayed kinetics of antigen processing and 
presentation with a time frame consistent with cross presentation (34). Further, we deliver 
PADRE, which is a universal CD4
+
 T cell eliciting epitope, in the same polyepitope 
protein as our CD8
+
 T cell eliciting epitopes that trigger an MHC Class I eliciting 
immune response. PADRE from this constructed protein also does enter a Class II 
pathway so either some polyepitope is not entrapped or our delivery system must 
bifurcate to cross presentation to MHC Class I and II pathways. This is a novel and 
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important finding with broad implications for vaccine development when induction of 
immune responses with protective CD8
+
 T- cells are critical. 
 
Despite the protection afforded by vaccination regimens developed in this study, no 
preparation provided complete protection against T. gondii and some brain cysts and 
parasites in peritoneal fluid were still detected. There is room to improve the vaccine by 
adding the parasite immunogenic peptides, which generate parasite specific CD4
+ 
T cells. 
In addition the inclusion of B cell epitopes to induce antibodies might also help develop 
more robust vaccines against T. gondii. Antibodies have not been considered to be the 
primary protective mechanism for T. gondii, when compared to cell mediated immunity 
with the induction of cytolytic T cells and IFN-γ production (35, 36). Nonetheless, 
antibodies, including IgM have been implicated in killing extracellular parasites via 
inducing complement-dependent lysis or by blocking entry of parasites into host cells 
(37-39). 
 
In summary, our study shows a composite protein, with a secretory signal, five CD8
+
 
MHC class I epitopes from T. gondii, and PADRE, a universal CD4
+
 eliciting peptide, 
can be assembled and elicits protective MHC Class I, restricted responses. Using HLA-
A*1101 transgenic mice, we demonstrate the capacity and specificity of 5 HLA-A*1101 
restricted epitopes to prime and boost an IFN-g response. In addition, the recombinant 
multi-epitope polypeptide emulsified in GLA-SE adjuvant confers more protection and 
increases memory CD8
+
 T cell response against T. gondii in HLA-A*1101 transgenic 
mice. Previous studies have found that GLA-SE, formulated with the recombinant fatty 
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acid binding protein Sm14 enhances Th-1 type responses. Production of IFN-g was the 
basis of Sm-14 mediated protective immunity both in humans with schistosomiasis and 
animal models (40). This Sm14 anti-schistosome vaccine is safe and entering phase 2 
trials in Brazil and Africa. In our study, it is likely that the GLA-SE emulsion encloses 
the protein and presents an optimum configuration decorated with the TLR4 ligand GLA 
that induces a powerful CD8
+
 and CD4
+
 T cell immune response (Figure 8). In addition, 
DNA encoding the multi-epitope delivered by electroporation and followed by protein 
boosts is useful for the induction of a strong immune response against T. gondii. Thus, 
our data provide important support suggesting that enhanced electroporation-delivered 
DNA prime-protein boost, and protein prime protein boost which would be considerably 
better tolerated, are useful strategies for delivery of a multi-epitope anti-apicomplexan 
parasite vaccine. As these epitopes for immunization are tailored to HLA and the efficacy 
of vaccination with these epitopes is evaluated in mice expressing an HLA molecule, they 
provide a foundation and promise as a vaccine for humans. Potential improvements to 
this vaccine might be made with the addition of epitopes from various T. gondii proteins 
encompassing several of the parasite life stages and polymorphogenetic strains in a single 
platform that could elicit a protective immune response for the HLA class I and II 
supermotifs present for all the human population. 
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METHODS 
Bioinformatic predictions and MHC-peptide binding assays 
Protein sequences derived from SAG1, SRS52A, SAG2C, GRA6, and GRA5 were 
analyzed for CD8
+
 T cell epitopes based on predicted binding affinity to HLA-A*1101 
molecules using algorithms available at the Immune Epitope database (IEDB) 
http://www.iedb.org (41, 42). Quantitative assays to measure binding of peptides to HLA 
class I molecules are based on inhibition of binding of radiolabeled standard peptide. 
Assays were performed as described previously (43, 44). Concentration of peptide 
yielding 50% inhibition of binding of radiolabeled probe peptide (IC50) was calculated. 
Under the conditions utilized, were where [label]<[MHC] and IC50, [MHC], the 
measured IC50 values are reasonable approximations of the true Kd values. 
 
Human PBMC and ELISpot assay 
PBMC were obtained from individuals seropositive to T. gondii, and their HLA 
haplotype was determined. These cells were processed and cryopreserved as described 
previously (3). ELISpot assays with human PBMCs used anti-human IFN-γ mAb (1-
D1K) with biotinylated anti-human IFN-γ mAb (7B6-1) with 2 × 10
5
 PBMCs per well (5, 
6). All antibodies and reagents used for ELISpot assays were from Mabtech (Cincinnati, 
OH). The PBMC were plated in at least 3 replicate wells for each condition. Results were 
expressed as number of spot forming cells (SFCs) per 10
6 
PBMCs. 
 
Epitope peptides 
KSFKDILPK (SAG1224-232), STFWPCLLR (SAG2C13-21), AVVSLLRLLK (GRA589-98), 
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SSAYVFSVK (SRS52A250-258), AMLTAFFLR (GRA6164-172) and PADRE-derived 
universal CD4 helper epitope (AKFVAAWTLKAAA) were used in the vaccine 
constructs (45). GLA-SE adjuvant (TLR4 agonist), synthesized by the Infectious 
Diseases Research Institute (Seattle, Washington) was used as a stable oil-in-water 
emulsion with specified epitopes during immunization. 
 
Multi-epitope DNA vaccine design 
To maximize epitope immunogenicity in vivo, the peptides encoding minigene included 
starting codon ATG and the mouse Ig k signal sequence at the 5Õ end of the construct, 
and spacer sequences N/AAA (LO construct) and GPGPG (AZ construct) residues 
flanking the C-terminus of all epitopes (Figures 3 A-C). Whereas the former facilitates 
processing of the CTL epitopes in the ER, the latter favors proper proteasomal processing 
and prevents the formation of junctional HLA epitopes. The order of the CTL and HTL 
epitopes in the minigene and type of spacer sequences that favor proper proteasomal 
cleavage were determined by a customized computer software program (Epimmune) that 
identifies the most favorable sequence for epitope processing and simultaneously 
minimizes the creation of new junctional HLA-A11 determinants. 
 
Purification of multi-epitope protein vaccine 
LO and AZ DNA were PCR-amplified and cloned in the expression vector pET-22 
(Novagen). The multi-epitope protein was expressed in the Escherichia coli BL21-
CodonPlus strain (Stratagene). Expression clones were grown at 37¡C in Luria broth 
medium containing 50 µg/µl kanamycin and 34 µg/µl chloramphenicol. A 1-liter culture 
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of E. coli was grown to an A600 of 0.6, and protein expression was induced by addition of 
isopropyl-β-D-thiogalactopyranoside (1mM final concentration). Recombinant protein 
was extracted under native conditions by using the BugBuster protein extraction reagent 
(Novagen, 6 ml/g of cell pellet) containing a protease inhibitor mix (Roche Diagnostics) 
and 10µg/ml lysozyme. All purification steps were performed under 8 M urea denaturing 
conditions. The His-tagged polypeptides were purified by using nickel-affinity 
chromatography and followed by Q-Sepharose, which used to capture the endotoxin. The 
eluate, which contains 8 M urea, was dialyzed against a buffer containing 5 mM Hepes-
KOH (pH 7.8) and 0.5 mM DTT. The purity of the protein was determined by SDS-
PAGE, and the protein concentration was measured by the method of Bradford using 
BSA as a standard. Using E-TOXATE Kits (Sigma-Aldrich, USA), endotoxin 
concentration in these proteins is <25EU/ug of protein. 
 
Plasmid and gene cloning of multi-epitopes DNA vaccine construct 
The clinically approved mammalian expression vector pMB75.6 (from Inovio 
Pharmaceuticals, Blue Bell, PA) was used as a DNA vaccine vector (25). Briefly, the 
plasmid contains elements essential for expression in mammalian cells: a 
cytomegalovirus (CMV) promoter, intron, and gene of interest followed by the simian 
virus 40 (SV40) polyadenylation signal. 
 
The oligonucleotides of 5 individual T. gondii peptides shown in Table 1 plus PADRE-
derived universal CD4 helper epitope were linked with different spacers and synthesized 
using 9 overlapping 50-nucleotide oligonucleotides. LO and AZ were first assembled and 
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amplified as three small fragments that were subsequently used as templates to amplify 
the whole gene. The full-length constructs were cloned into the vaccine vector pMB75.6 
using EcoRI/BglII restriction sites. Neither the pMB75.6 vector backbone nor the 
epitope-encoding region shares significant homology with known human genomic 
sequences. All recombinant plasmids were propagated in Escherichia coli TOP10 and 
confirmed by restriction analysis and PCR sequencing. Large-scale plasmid DNA was 
prepared using the endotoxin-free Mega kit according to the manufacturerÕs instructions 
(Qiagen, Hilden, Germany), and the DNA concentrations were determined by 
A260/A280 absorption measurements. Plasmid DNA was dissolved in sterile endotoxin-
free PBS and stored at -20¡C until use. 
 
Mice 
HLA-A*1101/K
b
 transgenic mice were produced at Pharmexa-Epimmune (San Diego, 
CA), embryo-rederived at Taconic and JAX laboratories and bred at the University of 
Chicago. These HLA-A*1101/K
b
 transgenic mice express a chimeric gene consisting of 
the 1
st
 and 2
nd
 domains of HLA-A*1101 and the 3
rd
 domain of H-2K
b
, and were created 
on a C57BL/6 background. Mice were maintained in SPF conditions throughout. All 
studies were conducted with the approval of the Institutional Animal Care and Use 
Committee at the University of Chicago. 
 
Immunizations of mice and challenge 
To evaluate multi-epitope protein immunogenicity, HLA-A*1101 transgenic mice were 
inoculated subcutaneously (s.c.) at the base of the tail using a 30-gauge needle with 50 µg 
 27 
LO or AZ recombinant protein emulsified in 20 µg of GLA-SE (TLR4 agonist) three 
times at two weeks intervals. For immunization by DNA, mice were inoculated by 
injection of 50 µl of PBS containing 100 µg of DNA into each quadriceps muscle using a 
G26 gauge needle at weeks 0, 2 and 4. In a bid to enhance delivery of DNA, we used an 
electroporation device. Briefly, following injection of DNA, the surface dermal device 
was applied to the site of injection as described (46). The array was ÒwiggledÓ at the 
injection site to ensure good contact and electro-transfer achieved through pulse 
generation from the ELGEN 1000 (Inovio Pharm., San Diego) pulse generator. The 
parameters used were three 15 V pulses of 100 ms duration. Negative control mice were 
vaccinated with 100µg empty vector or 50µl saline. For challenge studies, immunized 
mice were challenged intraperitoneally (i.p.) 14 days post-immunization using 2,000 or 
20,000 T. gondii ME49-Fluc (Type II) parasites that express firefly luciferase. 
 
ELISpot assay to determine immune responses with murine splenocytes 
Mice were euthanized 14 days after immunization. Spleens were harvested, pressed 
through a 70 µm screen to form a single-cell suspension, and erythrocytes were lysed 
with AKC lysis buffer (160 mM NH4Cl, 10 mM KHCO3, 100 mM EDTA). Splenocytes 
were washed twice with HankÕs Balanced Salt Solution (HBSS) and resuspended in 
complete RPMI medium (RPMI-1640 supplemented with 2 mM L-GlutaMax (Life 
technologies). Murine ELISPOT assays were performed using anti-mouse IFN-γ mAb 
(AN18) and the biotinylated anti-mouse IFN-γ mAb (R4Ð6A2) and 2.5-5×10
5
 
splenocytes were plated per well. All antibodies and reagents used for the ELISPOT 
assay were obtained from Mabtech (Cincinnati, OH). Cells were plated in at least 3 
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replicate wells for each condition. Results were expressed as the number of spot forming 
cells (SFCs) per 10
6
 murine splenocytes. 
 
In vivo bioluminescence imaging for determining outcomes of challenge with type II 
parasites 
Mice infected with 2,000 T. gondii ME49-Fluc (Type II) tachyzoites were imaged 21 
days post-challenge using the in vivo imaging system (IVIS; Xenogen, Alameda, CA). 
Mice were injected retroorbitally with 200 µl (15.4mg/ml) of D-luciferin, anesthetized in 
an O2-rich induction chamber with 2% isoflurane, and imaged after 12 minutes. Photonic 
emissions were assessed using Living image¨ 2.20.1 software (Xenogen). Data are 
presented as pseudocolor representations of light intensity and mean photons/region of 
interest (ROI). All mouse experiments were repeated at least twice. 
 
Enumeration of cysts in mouse brains following type II parasite challenge 
Mice were euthanized at 21 days after infection with 2,000 of Me49-Fluc, and brains 
were collected, homogenized with 1 ml of saline (0.85% NaCl). Tissue cysts were 
counted microscopically in 50 µl of the homogenate, and the count was multiplied by 20 
to obtain the number of tissue cysts per brain. This number was confirmed by staining 
brain cysts with fluorescein-labeled Dolichos biflorus agglutinin (Vector Laboratories) 
and quantitation using fluorescence microscopy. 
 
Flow cytometry. 
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Splenocytes were manually processed using 70µm filters in DMEM media supplemented 
with 5% FCS and red blood cells were lysed with ACK lysis buffer. Cells were stained 
with CD3 APC (145-2C11), CD4 PE (GK1.5), CD8 PerCP (53-6.7), and CD44 AF780 
(IM7), CD45RB FITC (C363.16A). All antibodies were purchased from eBioscience 
(San Diego, CA). Memory T cells were defined as CD44
hi
CD45RB
lo
. All flow cytometry 
data was collected on LSRII flow cytometer (BD Biosciences, San Jose, CA) and 
analyzed using FlowJo software 10.0 (Tree Star, Ashland, OR). 
 
Demonstration that GLA is a TLR 4 ligand. 
Stimulation of human whole blood with GLA-SE. Heparinized whole blood was 
collected from six healthy donors, and 200 µl was stimulated with 5 µg GLA-SE in 96-
well plates at 37
o
C-CO2. After 24 hours, plasma was removed and assayed for IL-6, IL-
12(p40), and TNF by a custom Luminex-based multiplex immunoassay kit (Affymetrix 
eBioscience, San Diego, CA). Data was analyzed using the Masterplex QT software 
(Miraibio, San Francisco, CA). The cytokine production stimulated by adjuvant was 
statistically significant (p<0.05) compared to the unstimulated groups as assessed by the 
Mann-Whitney t-test (GraphPad Prism software, San Diego, CA). 
 
Statistical analyses 
Data for each assay were compared by One-way ANOVA or a Student t test using 
GraphPad Prism 5 software (GraphPad Software, San Diego, CA). Differences between 
the groups were identified by ANOVA and multiple comparison procedures, as we 
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previously described (6). Data are expressed as the means ± SD. Results were considered 
to be statistically significant at p < 0.05. 
 
Study approval 
Experiments and handling of mice were conducted under federal, state, and local 
guidelines under an IACUC protocol and with approval from the University of Chicago 
IACUC. 
Institutional Review Board (IRB) approval was obtained at the University of Chicago for 
this study. This study also is in compliance with all Health Insurance Portability and 
Accountability Act of 1996 (HIPAA) regulations. 
 31 
Author Contributions 
KE, AC, PK, YZ, SW, JD, CR, EM, YS, QS, SB, NC, and LF performed experiments. 
LV and KB contributed essential reagents or tools. JS, SR, JA, TV, AS analyzed and 
interpreted data. KE and RM supervised the work, interpreted the data, and wrote the 
manuscript. 
The authors declare no competing interests. 
 32 
Acknowledgements 
We gratefully acknowledge support of this work from the Mann Cornwell, Engel. Morel, 
Pritzker, Harris, Rooney-Alden, Langel, Samuel, and Mussilami families. This work was 
supported by DMID-NIAID U01 AI77887, R01 27530 (to RM), Knights Templar Eye 
Foundation (to KE), and The Research to Prevent Blindness Foundation (to RM). We 
thank I.J. Begeman for his assistance with the preparation of this manuscript. 
The funding sources had no influence in study design; in the collection, analysis and 
interpretation of data; in the writing of the report; and in the decision to submit the paper 
for publication. 
 33 
REFERENCES 
1.	 McLeod	 R,	 Kieffer	 F,	 Sautter	 M,	 Hosten	 T,	 and	 Pelloux	 H.	 Why	 prevent,	
diagnose	 and	 treat	 congenital	 toxoplasmosis?	 Mem	 Inst	 Oswaldo	 Cruz.	
2009;104(2):320-44.	
2.	 McAuley	J,	Boyer	KM,	Patel	D,	Mets	M,	Swisher	C,	Roizen	N,	Wolters	C,	Stein	L,	
Stein	M,	Schey	W,	et	al.	Early	and	longitudinal	evaluations	of	treated	infants	
and	 children	 and	 untreated	 historical	 patients	 with	 congenital	
toxoplasmosis:	 the	 Chicago	 Collaborative	 Treatment	 Trial.	 Clin	 Infect	 Dis.	
1994;18(1):38-72.	
3.	 Tan	 TG,	 Mui	 E,	 Cong	 H,	 Witola	 WH,	 Montpetit	 A,	 Muench	 SP,	 Sidney	 J,	
Alexander	 J,	 Sette	 A,	 Grigg	 ME,	 et	 al.	 Identification	 of	 T.	 gondii	 epitopes,	
adjuvants,	 and	 host	 genetic	 factors	 that	 influence	 protection	 of	 mice	 and	
humans.	Vaccine.	2010;28(23):3977-89.	
4.	 Cong	H,	Mui	EJ,	Witola	WH,	Sidney	J,	Alexander	J,	Sette	A,	Maewal	A,	El	Bissati	
K,	 Zhou	 Y,	 Suzuki	 Y,	 et	 al.	 Toxoplasma	 gondii	 HLA-B*0702-restricted	
GRA7(20-28)	 peptide	with	 adjuvants	 and	 a	 universal	 helper	 T	 cell	 epitope	
elicits	 CD8(+)	 T	 cells	 producing	 interferon-gamma	 and	 reduces	 parasite	
burden	in	HLA-B*0702	mice.	Hum	Immunol.	2012;73(1):1-10.	
5.	 Cong	 H,	 Mui	 EJ,	 Witola	WH,	 Sidney	 J,	 Alexander	 J,	 Sette	 A,	 Maewal	 A,	 and	
McLeod	R.	Human	immunome,	bioinformatic	analyses	using	HLA	supermotifs	
and	the	parasite	genome,	binding	assays,	studies	of	human	T	cell	responses,	
and	immunization	of	HLA-A*1101	transgenic	mice	including	novel	adjuvants	
provide	 a	 foundation	 for	 HLA-A03	 restricted	 CD8+T	 cell	 epitope	 based,	
adjuvanted	 vaccine	 protective	 against	 Toxoplasma	 gondii.	 Immunome	 Res.	
2010;6(12.	
6.	 Cong	 H,	 Mui	 EJ,	 Witola	WH,	 Sidney	 J,	 Alexander	 J,	 Sette	 A,	 Maewal	 A,	 and	
McLeod	 R.	 Towards	 an	 immunosense	 vaccine	 to	 prevent	 toxoplasmosis:	
protective	 Toxoplasma	 gondii	 epitopes	 restricted	 by	 HLA-A*0201.	Vaccine.	
2011;29(4):754-62.	
7.	 Mineo	 JR,	 and	 Kasper	 LH.	 Attachment	 of	 Toxoplasma	 gondii	 to	 host	 cells	
involves	major	 surface	 protein,	 SAG-1	 (P30).	Exp	 Parasitol.	 1994;79(1):11-
20.	
8.	 Kasper	 LH,	 and	 Mineo	 JR.	 Attachment	 and	 invasion	 of	 host	 cells	 by	
Toxoplasma	gondii.	Parasitol	Today.	1994;10(5):184-8.	
9.	 Nielsen	 HV,	 Lauemoller	 SL,	 Christiansen	 L,	 Buus	 S,	 Fomsgaard	 A,	 and	
Petersen	E.	Complete	protection	against	 lethal	Toxoplasma	gondii	 infection	
in	mice	 immunized	with	 a	 plasmid	 encoding	 the	 SAG1	 gene.	 Infect	 Immun.	
1999;67(12):6358-63.	
10.	 Lane	A,	Soete	M,	Dubremetz	JF,	and	Smith	JE.	Toxoplasma	gondii:	appearance	
of	specific	markers	during	the	development	of	tissue	cysts	in	vitro.	Parasitol	
Res.	1996;82(4):340-6.	
11.	 Donnelly	JJ,	Wahren	B,	and	Liu	MA.	DNA	vaccines:	progress	and	challenges.	J	
Immunol.	2005;175(2):633-9.	
12.	 El	Bissati	K,	Zhou	Y,	Dasgupta	D,	Cobb	D,	Dubey	JP,	Burkhard	P,	Lanar	DE,	and	
McLeod	R.	 Effectiveness	 of	 a	 novel	 immunogenic	 nanoparticle	 platform	 for	
 34 
Toxoplasma	 peptide	 vaccine	 in	 HLA	 transgenic	 mice.	 Vaccine.	
2014;32(26):3243-8.	
13.	 Kutzler	MA,	Kraynyak	KA,	Nagle	SJ,	Parkinson	RM,	Zharikova	D,	Chattergoon	
M,	Maguire	H,	Muthumani	K,	Ugen	K,	and	Weiner	DB.	Plasmids	encoding	the	
mucosal	 chemokines	 CCL27	 and	 CCL28	 are	 effective	 adjuvants	 in	 eliciting	
antigen-specific	immunity	in	vivo.	Gene	Ther.	2010;17(1):72-82.	
14.	 Lang	 Kuhs	 KA,	 Ginsberg	 AA,	 Yan	 J,	 Wiseman	 RW,	 Khan	 AS,	 Sardesai	 NY,	
O'Connor	 DH,	 and	 Weiner	 DB.	 Hepatitis	 C	 virus	 NS3/NS4A	 DNA	 vaccine	
induces	multiepitope	T	cell	responses	in	rhesus	macaques	mimicking	human	
immune	responses	[corrected].	Mol	Ther.	2012;20(3):669-78.	
15.	 Sardesai	 NY,	 and	 Weiner	 DB.	 Electroporation	 delivery	 of	 DNA	 vaccines:	
prospects	for	success.	Curr	Opin	Immunol.	2011;23(3):421-9.	
16.	 Muthumani	K,	Wise	MC,	Broderick	KE,	Hutnick	N,	Goodman	J,	Flingai	S,	Yan	J,	
Bian	CB,	Mendoza	J,	Tingey	C,	et	al.	HIV-1	Env	DNA	vaccine	plus	protein	boost	
delivered	by	EP	expands	B-	and	T-cell	responses	and	neutralizing	phenotype	
in	vivo.	PLoS	One.	2013;8(12):e84234.	
17.	 Brown	CR,	Hunter	CA,	Estes	RG,	Beckmann	E,	Forman	J,	David	C,	Remington	
JS,	 and	McLeod	R.	Definitive	 identification	of	 a	gene	 that	 confers	 resistance	
against	 Toxoplasma	 cyst	 burden	 and	 encephalitis.	 Immunology.	
1995;85(3):419-28.	
18.	 Roberts	F,	Roberts	CW,	Ferguson	DJ,	and	McLeod	R.	Inhibition	of	nitric	oxide	
production	 exacerbates	 chronic	 ocular	 toxoplasmosis.	 Parasite	 Immunol.	
2000;22(1):1-5.	
19.	 Kirisits	MJ,	Mui	E,	and	McLeod	R.	Measurement	of	the	efficacy	of	vaccines	and	
antimicrobial	 therapy	 against	 infection	 with	 Toxoplasma	 gondii.	 Int	 J	
Parasitol.	2000;30(2):149-55.	
20.	 Johnson	 J,	Suzuki	Y,	Mack	D,	Mui	E,	Estes	R,	David	C,	Skamene	E,	Forman	 J,	
and	 McLeod	 R.	 Genetic	 analysis	 of	 influences	 on	 survival	 following	
Toxoplasma	gondii	infection.	Int	J	Parasitol.	2002;32(2):179-85.	
21.	 Johnson	JJ,	Roberts	CW,	Pope	C,	Roberts	F,	Kirisits	MJ,	Estes	R,	Mui	E,	Krieger	
T,	Brown	CR,	Forman	J,	et	al.	In	vitro	correlates	of	Ld-restricted	resistance	to	
toxoplasmic	 encephalitis	 and	 their	 critical	 dependence	 on	 parasite	 strain.	 J	
Immunol.	2002;169(2):966-73.	
22.	 Dubey	JP,	Ferreira	LR,	Martins	J,	and	McLeod	R.	Oral	oocyst-induced	mouse	
model	of	toxoplasmosis:	effect	of	infection	with	Toxoplasma	gondii	strains	of	
different	genotypes,	dose,	and	mouse	strains	(transgenic,	out-bred,	 in-bred)	
on	pathogenesis	and	mortality.	Parasitology.	2012;139(1):1-13.	
23.	 McLeod	 R,	 Frenkel	 JK,	 Estes	 RG,	 Mack	 DG,	 Eisenhauer	 PB,	 and	 Gibori	 G.	
Subcutaneous	 and	 intestinal	 vaccination	 with	 tachyzoites	 of	 Toxoplasma	
gondii	 and	 acquisition	 of	 immunity	 to	 peroral	 and	 congenital	 toxoplasma	
challenge.	J	Immunol.	1988;140(5):1632-7.	
24.	 Lyons	 RE,	 Anthony	 JP,	 Ferguson	 DJ,	 Byrne	 N,	 Alexander	 J,	 Roberts	 F,	 and	
Roberts	 CW.	 Immunological	 studies	 of	 chronic	 ocular	 toxoplasmosis:	 up-
regulation	 of	 major	 histocompatibility	 complex	 class	 I	 and	 transforming	
growth	 factor	 beta	 and	 a	 protective	 role	 for	 interleukin-6.	 Infect	 Immun.	
2001;69(4):2589-95.	
 35 
25.	 Wilson	 CC,	 McKinney	 D,	 Anders	 M,	 MaWhinney	 S,	 Forster	 J,	 Crimi	 C,	
Southwood	S,	Sette	A,	Chesnut	R,	Newman	MJ,	et	al.	Development	of	a	DNA	
vaccine	 designed	 to	 induce	 cytotoxic	 T	 lymphocyte	 responses	 to	 multiple	
conserved	epitopes	in	HIV-1.	J	Immunol.	2003;171(10):5611-23.	
26.	 Livingston	 BD,	 Newman	 M,	 Crimi	 C,	 McKinney	 D,	 Chesnut	 R,	 and	 Sette	 A.	
Optimization	 of	 epitope	 processing	 enhances	 immunogenicity	 of	
multiepitope	DNA	vaccines.	Vaccine.	2001;19(32):4652-60.	
27.	 Feliu	V,	Vasseur	V,	Grover	HS,	Chu	HH,	Brown	MJ,	Wang	J,	Boyle	JP,	Robey	EA,	
Shastri	 N,	 and	 Blanchard	 N.	 Location	 of	 the	 CD8	 T	 cell	 epitope	 within	 the	
antigenic	 precursor	 determines	 immunogenicity	 and	protection	 against	 the	
Toxoplasma	gondii	parasite.	PLoS	Pathog.	2013;9(6):e1003449.	
28.	 Ochoa-Reparaz	 J,	 and	 Kasper	 LH.	 Gut	 microbiome	 and	 the	 risk	 factors	 in	
central	nervous	system	autoimmunity.	FEBS	Lett.	2014;588(22):4214-22.	
29.	 Telesford	K,	Ochoa-Reparaz	J,	and	Kasper	LH.	Gut	commensalism,	cytokines,	
and	 central	 nervous	 system	 demyelination.	 J	 Interferon	 Cytokine	 Res.	
2014;34(8):605-14.	
30.	 Wang	Y,	Telesford	KM,	Ochoa-Reparaz	J,	Haque-Begum	S,	Christy	M,	Kasper	
EJ,	 Wang	 L,	 Wu	 Y,	 Robson	 SC,	 Kasper	 DL,	 et	 al.	 An	 intestinal	 commensal	
symbiosis	 factor	 controls	 neuroinflammation	 via	 TLR2-mediated	 CD39	
signalling.	Nat	Commun.	2014;5(4432.	
31.	 van	Haren	 SD,	Ganapathi	 L,	Bergelson	 I,	Dowling	DJ,	 Banks	M,	 Samuels	RC,	
Reed	 SG,	 Marshall	 JD,	 and	 Levy	 O.	 In	 vitro	 cytokine	 induction	 by	 TLR-
activating	 vaccine	 adjuvants	 in	 human	 blood	 varies	 by	 age	 and	 adjuvant.	
Cytokine.	2016;83(99-109.	
32.	 Coler	RN,	Duthie	MS,	Hofmeyer	KA,	Guderian	J,	Jayashankar	L,	Vergara	J,	Rolf	
T,	 Misquith	 A,	 Laurance	 JD,	 Raman	 VS,	 et	 al.	 From	 mouse	 to	 man:	 safety,	
immunogenicity	 and	 efficacy	 of	 a	 candidate	 leishmaniasis	 vaccine	 LEISH-
F3+GLA-SE.	Clin	Transl	Immunology.	2015;4(4):e35.	
33.	 Roberts	 CW,	 Prasad	 S,	 Khaliq	 F,	 Gazzinelli	 RT,	 Khan	 IA,	 and	McLeod	 R.	 In:	
Weiss	 LM,	 and	 Kim	 K	 eds.	 Toxoplasma	 gondii	 :	 the	 model	 apicomplexan	 -	
perspectives	and	methods.	Amsterdam:	Elsevier/AP;	2014:819-994.	
34.	 McCoy	ME,	Golden	HE,	Doll	TA,	Yang	Y,	Kaba	SA,	Zou	X,	Gerbasi	VR,	Burkhard	
P,	and	Lanar	DE.	Mechanisms	of	protective	immune	responses	induced	by	the	
Plasmodium	 falciparum	 circumsporozoite	 protein-based,	 self-assembling	
protein	nanoparticle	vaccine.	Malar	J.	2013;12(1):136.	
35.	 Gazzinelli	RT,	Hakim	FT,	Hieny	S,	Shearer	GM,	and	Sher	A.	Synergistic	role	of	
CD4+	 and	 CD8+	 T	 lymphocytes	 in	 IFN-gamma	 production	 and	 protective	
immunity	 induced	by	an	attenuated	Toxoplasma	gondii	 vaccine.	 J	 Immunol.	
1991;146(1):286-92.	
36.	 Suzuki	Y,	Orellana	MA,	Schreiber	RD,	and	Remington	 JS.	 Interferon-gamma:	
the	 major	 mediator	 of	 resistance	 against	 Toxoplasma	 gondii.	 Science.	
1988;240(4851):516-8.	
37.	 Couper	 KN,	 Roberts	 CW,	 Brombacher	 F,	 Alexander	 J,	 and	 Johnson	 LL.	
Toxoplasma	gondii-specific	immunoglobulin	M	limits	parasite	dissemination	
by	preventing	host	cell	invasion.	Infect	Immun.	2005;73(12):8060-8.	
 36 
38.	 Mack	 DG,	 and	 McLeod	 R.	 Human	 Toxoplasma	 gondii-specific	 secretory	
immunoglobulin	A	 reduces	T.	 gondii	 infection	of	 enterocytes	 in	 vitro.	 J	 Clin	
Invest.	1992;90(6):2585-92.	
39.	 Mineo	 JR,	 McLeod	 R,	 Mack	 D,	 Smith	 J,	 Khan	 IA,	 Ely	 KH,	 and	 Kasper	 LH.	
Antibodies	to	Toxoplasma	gondii	major	surface	protein	(SAG-1,	P30)	inhibit	
infection	 of	 host	 cells	 and	 are	 produced	 in	 murine	 intestine	 after	 peroral	
infection.	J	Immunol.	1993;150(9):3951-64.	
40.	 Tendler	 M,	 Almeida	 M,	 and	 Simpson	 A.	 Development	 of	 the	 Brazilian	 Anti	
Schistosomiasis	 Vaccine	 Based	 on	 the	 Recombinant	 Fatty	 Acid	 Binding	
Protein	Sm14	Plus	GLA-SE	Adjuvant.	Front	Immunol.	2015;6(218.	
41.	 Moutaftsi	M,	 Peters	B,	 Pasquetto	V,	 Tscharke	DC,	 Sidney	 J,	 Bui	HH,	Grey	H,	
and	Sette	A.	A	consensus	epitope	prediction	approach	identifies	the	breadth	
of	 murine	 T(CD8+)-cell	 responses	 to	 vaccinia	 virus.	 Nat	 Biotechnol.	
2006;24(7):817-9.	
42.	 Gulukota	K,	Sidney	J,	Sette	A,	and	DeLisi	C.	Two	complementary	methods	for	
predicting	 peptides	 binding	 major	 histocompatibility	 complex	 molecules.	 J	
Mol	Biol.	1997;267(5):1258-67.	
43.	 Sidney	 J,	 Assarsson	 E,	 Moore	 C,	 Ngo	 S,	 Pinilla	 C,	 Sette	 A,	 and	 Peters	 B.	
Quantitative	 peptide	 binding	motifs	 for	 19	 human	 and	mouse	MHC	 class	 I	
molecules	derived	using	positional	scanning	combinatorial	peptide	libraries.	
Immunome	Res.	2008;4(2.	
44.	 Sidney	 J,	 Southwood	 S,	 Oseroff	 C,	 del	 Guercio	 MF,	 Sette	 A,	 and	 Grey	 HM.	
Measurement	 of	 MHC/peptide	 interactions	 by	 gel	 filtration.	 Curr	 Protoc	
Immunol.	2001;Chapter	18(Unit	18	3.	
45.	 Alexander	J,	Sidney	J,	Southwood	S,	Ruppert	J,	Oseroff	C,	Maewal	A,	Snoke	K,	
Serra	HM,	Kubo	RT,	Sette	A,	et	al.	Development	of	high	potency	universal	DR-
restricted	 helper	 epitopes	 by	 modification	 of	 high	 affinity	 DR-blocking	
peptides.	Immunity.	1994;1(9):751-61.	
46.	 Broderick	KE,	Shen	X,	Soderholm	 J,	Lin	F,	McCoy	 J,	Khan	AS,	Yan	 J,	Morrow	
MP,	 Patel	 A,	 Kobinger	 GP,	 et	 al.	 Prototype	 development	 and	 preclinical	
immunogenicity	 analysis	 of	 a	 novel	 minimally	 invasive	 electroporation	
device.	Gene	Ther.	2011;18(3):258-65.	
 
  
 37 
Table 1. HLA-A*1101 restricted CD8+ T-cell epitopes predicted IC50 within the T. 
gondii protein GRA6, SAG2C, SAG1, GRA5 sequences and utilized for 
recombinant DNA and protein constructs and affinity of binding. 
 
Peptide Sequencea MW 
Affinity (IC50, nM) 
A*1101 A*02.01 B*07.02 
SAG2C13-21 STFWPCLLR 1122 9.3 26987 >50,000 
GRA589-98 AVVSLLRLLK 1111 6.5 11326 >50,000 
SRS52A250-258 SSAYVFSVK 987 9.3 >50,000 >50,000 
SAG1224-232 KSFKDILPK 1075 35 >50,000 >50,000 
GRA6164-172 AMLTAFFLR 1069 3.6 10563 >50,000 
 
a Position of each peptide relative to the full length proteins (GRA6, SAG2C, SAG1, 
GRA5, and SRS52A) including the signal sequence, their molecular weight (MW), and 
the predicted IC50 as calculated by in vitro binding affinity to purified HLA-A*1101 
molecules expressed as means of binding capacities (IC50 nM) determined from two 
independent experiments, as previously described (5) and for A*02.01 and B*07.02. 
None of the peptides would be considered an A*02.01 or B*07.02 binder. 
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Table 2. IFN-γ production of CD8+ T cells purified from the spleens of HLA-A*1101 
transgenic mice immunized three times with T. gondii epitope peptides at two 
weeks intervals following stimulation with the peptides in vitro. 
 
HLA-A*1101 Mice Immunized 
in vivo with 
Stimulated in vitro 
with 
APC* IFN-γ** (ng/mL) 
Peptides + GLA-SE+ Peptides HLA-A*1101 3.06 ± 0.90 
GLA-SE+ Peptides HLA-A*1101 0.17 ± 0.23 
PBS Peptides HLA-A*1101 0.12 ± 0.12 
Peptides + GLA-SE+ PBS HLA-A*1101 0.31 ± 0.20 
GLA-SE+ PBS HLA-A*1101 0.030 ± 0.015 
PBS PBS HLA-A*1101 0.24 ± 0.17 
Peptides + GLA-SE+ Peptides C57BL/6 0.040 ± 0.038 
GLA-SE+ Peptides C57BL/6 0.025 ± 0.038 
PBS Peptides C57BL/6 0.030 ± 0.040 
Peptides + GLA-SE PBS C57BL/6 0.020 ± 0.031 
GLA-SE PBS C57BL/6 0.00 ± 0.00 
PBS PBS C57BL/6 0.095 ± 0.038 
 
Mice were immunized with PBS, peptide pool (KSFKDILPK (SAG1224-232), STFWPCLLR 
(SAG2C13-21), AVVSLLRLLK (GRA589-98), SSAYVFSVK (SRS52A250-258), AMLTAFFLR 
(GRA6164-172), RSFKDLLKK (GRA7134-142) with PADRE, 
+ (Pam)2KSS (5) plus in GLA-SE, 
and GLA-SE alone. * Adherent cells from spleens of mice. ** Concentrations in the 
culture supernatants. 
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Figure 1: New peptides tested with PBMCs from HLA-A03 seropositive and seronegative donors. The peripheral
blood mononuclear cells from seropositive T. gondii donors were tested for response to these predicted HLA-A03
restricted CD8+ T cell epitope individual peptides by using IFN-g ELISpot assay. Concanavalin A (Con A) and
Tachyzoite Antigen Lysates (TLA) were used as controls.
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Figure 2: Immunogenicity and efficacy of 5 identified A11-restricted CD8+ T cell epitope pool
peptides in combination with PADRE and GLA-SE adjuvant in HLA-A*1101 transgenic mice. A, T.
gondii brain cysts was significantly reduced in HLA-A*1101 mice immunized with pool of peptides plus
PADRE and GLA-SE adjuvant at 21 days after challenge with 2000 T. gondii ME49-Fluc (Type II)
parasites. B, Quantitative real time PCR for the parasite burden in the T. gondii challenged HLA-A*1101
mice brains. C-D, Flow cytometry gating for CD8+ memory T cells 11 weeks after immunization of HLA-
A*1101 mice with pooled adjuvanted peptides. Cells are gated on CD3+CD8+ T cells. Memory T cells were
defined as CD44hiCD45RBlo. For each group, a representative FACS plot is shown with the percent of
CD8+ memory T cells shown. For each group, n=3.
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Figure 3: Schematic diagram of the DNA vaccine construct. A and B, The orientation of the HLA-
A*1101-restricted CD8+ T cell epitopes and PADRE in the synthetic gene is shown with two different types
of spacers, called LO and AZ for respectively N/KAAA and GPGPG linker. C, SDS-PAGE 4-20% of the
purified LO and AZ proteins.
Figure 4
IF
N
-γ
p
ro
d
u
c
in
g
 c
e
lls
 (
S
F
C
/1
0
6
c
e
lls
)
IF
N
-γ
p
ro
d
u
c
in
g
 c
e
lls
 (
S
F
C
/1
0
6
c
e
lls
)
B C
A
PBS Pool LO AZ CONA TLA
Stimulating in vitro
A11 seropositive
A11 seronegative
Figure 4: LO and AZ elicit specific immune responses in HLA-A03 seropositive and seronegative donors. A and B, ELISpot
showing IFN-g spot formation. PBMC’s were tested using LO, AZ, and pool of peptides. C, CONA and TLA were used as controls.
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Figure 5: Multivalent polypeptide LO and AZ protective efficacy in vivo HLA-A*1101 transgenic mice survival
curve after challenge with Type II parasites. Two weeks after last immunization, the transgenic mice immunized with
pooled LO and AZ proteins in combination with either adjuvant GLA-SE or ALUM adjuvant or injected with PBS were
infected with 2,000 Me49 (Fluc) parasites. The survival rates of the two groups were recorded. This figure shows data
from mice in both of the replicate experiments combined (n=5 control and 5 immunized mice).
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Figure 6: DNA prime-protein boost regimen. A, pMB75.6 vector used as a DNA vaccine vector for this study. Lane P: PMB75.6 plasmid, lane
2: PMB75.6 plasmid digested with EcoRI and BglII, lane M: KB ladder. B, T. gondii brain cysts luciferase expression was significantly reduced in
HLA-A*1101 mice immunized with DNA/ protein boost at 21 days after challenge with 2000 T. gondii ME49-Fluc (Type II) expressing luciferase.
C, Xenogen imaging of brain ex vivo following the injection of luciferin into the retroorbital plexus and then exposure of the brain to luciferin
solution. D, Enumeration of cyst was performed with brains of mice challenged 21 days after final immunization. These experiments were
performed at least two times, and each (n=5 control and 5 immunized mice). *,**,*** = p<0.05.
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Figure 7: CD8+ T cell responses in HLA-A*1101 mice following immunization. A, splenocytes from immunized mice with LO DNA, AZ DNA, multi-epitope polypeptides alone or combined were
harvested for 10–14 days post immunization and exposed to LO or AZ polypeptide in an ex vivo IFN-γ expression. B, (B) HLA-A*1101 transgenic mice survival curve after challenge with Type II
parasites. Two weeks after last immunization, the transgenic mice immunized with empty vector, LO DNA plus LO polypeptide, LO polypeptide or injected with PBS were infected with 2,000 T. gondii
ME49-Fluc (Type II) parasites. The survival rates of the two groups were recorded. Differences in survival were significant (p<0.03). This figure shows data from mice in one of the replicate
experiments (n=8 control and 8 immunized mice). C-D: CD8+ memory T cells. Flow cytometry gating for CD8+ memory T cells. Spleen cells are gated on CD3+CD8+ T cells. Memory T cells were
defined as CD44hiCD45RBlo. For each group, a representative FACS plot is shown with the percent of CD8+ memory T cells shown. All mouse experiments were repeated at least twice (n= 2-4 mice
in each group).
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Figure 8: Multi-epitope adjuvanted to GLA-SE are captured and presented by MHC molecules on the on the APCs to T lymphocytes. A. HLA-A*1101 transgenic mice immunized with LO
protein plus GLA-SE were protected compared to control mice inoculated with PBS when they were challenged with 10,000 T. gondii Prugneaud strain (Fluc) luciferase expressing parasites after 4
and 6 days. B. Stimulation of human whole blood with GLA-SE. Heparinized whole blood was collected from six healthy donors, and 200 µl was stimulated with 5 µg GLA-SE in 96-well plates at
37oC-CO2. After 24 hours, plasma was removed and assayed for IL-6, IL-12(p40), and TNF by a custom Luminex-based multiplex immunoassay kit (Affymetrix eBioscience, San Diego, CA). Data
was analyzed using the Masterplex QT software (Miraibio, San Francisco, CA). The cytokine production stimulated by adjuvant was statistically significant (p<0.05) compared to the unstimulated
groups as assessed by the Mann-Whitney t-test (GraphPad Prism software, San Diego, CA). C. Multi-epitope proteins with GLA-SE are captured and presented by MHC molecules on the Antigen-
presenting cells (APCs) to T lymphocytes. APCs are also activated through recognition of GLA-SE by TLR-4 receptors molecules. This activation leads to the production of proinflammatory cytokines
(IL-12, IL-6, TNF-a) and the expression of co-stimulatory molecules on the cell surface.
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